Health Care · Surgical & Medical Instruments & Apparatus

CLPT ClearPoint Neuro, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1285550132 filings
Russell 2000

CLPT at a glance

ClearPoint Neuro, Inc. (CLPT, SEC CIK 1285550) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90.
  • As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding ClearPoint Neuro, Inc. (CLPT) shares worth $73.6 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$37.0M
+17.8% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
19 funds
$73.6M · −2 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 1.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New risk: CAL preclinical CRO facility investment, triggered by ongoing build-out and operations
  • Operational risk: construction, permitting, equipment, or vendor delays could restrict CAL capacity and service offerings
  • Regulatory risk: failure to achieve or maintain GLP compliance could prevent GLP study performance
  • Market risk: insufficient customer demand or delayed statements of work could leave CAL underutilized
  • Financial risk: CAL lease expires approximately eleven years after final premises delivery, with fixed rent and annual increases

Management Discussion & Analysis

  • Q3 revenue $12.1M, up 36% YoY from $8.9M
  • Gross margin 58% vs 63% YoY, with gross profit $7.1M vs $5.6M
  • Best segment: neurosurgery navigation and therapy revenue $5.4M, up 59% YoY
  • Worst segment: biologics disposable products $1.2M, down 8% YoY
  • Cash $46.2M; nine-month operating cash use $20.1M, ATM proceeds $22.0M supporting liquidity for at least twelve months

AI summary of the CLPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • ATM equity capacity increased from $50 million to $150 million, expanding potential financing flexibility
  • Approximately $22.5 million sold, leaving roughly $27.5 million currently available under the existing prospectus
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $12.1M, up 36% year over year, with growth outpacing operating-expense growth of 23%
  • Neurosurgery navigation and therapy revenue $5.4M, up 59%, primarily reflecting IRRAflow sales after the IRRAS acquisition

Item EX-99.2: Item EX-99.2

  • Investor presentation outlines 2026 strategy, expanding from four to five growth pillars with commercial cell and gene therapy delivery
  • 2026 revenue guidance of $48.0-$50.0 million, versus $37.0 million in 2025

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for the quarter ended September 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation posted October 28, 2026, signaling refreshed messaging for analysts and investors
  • Presentation available as Exhibit 99.2 and intended for use in future investor communications
Filed Aug 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $10.9M, up 18% YoY, driven by neurosurgery navigation and therapy revenue growth of 62% to $5.6M
  • Biologics and drug delivery revenue fell 15% to $4.0M, reflecting lower biopharma trial-related product shipments

Item EX-99.2: Item EX-99.2

  • Investor presentation outlines a five-pillar strategy targeting $500m revenue, adding commercial drug delivery to four existing businesses
  • 2026 revenue guidance $48.0m-$52.0m, versus $37.0m in 2025

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation furnished as Exhibit 99.2, signaling refreshed messaging for investors and analysts
  • Presentation available on ClearPoint Neuro’s investor-relations website for review

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 financial results for quarter ended June 30, 2026 announced
  • Full revenue, earnings and operating details in Exhibit 99.1 press release

AI summaries of CLPT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CLPT

Don't miss the next CLPT filing

  • Alerts as it files. A push when CLPT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CLPT, by share count.
  • Ask anything. An AI agent that reads every CLPT filing and answers with sources.

CLPT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
FLETCHER R JOHNAOct 1, 2026$12.21
Richards Timothy T.AOct 1, 2026$12.21
BURNETT JOSEPHMSep 2, 2026-
BURNETT JOSEPHMSep 2, 2026$3.47
FLETCHER R JOHNAJul 1, 2026$17.84
Richards Timothy T.AJul 1, 2026$17.84
BURNETT JOSEPHAJun 30, 2026$11.93
D'Alessandro DaniloAJun 30, 2026$11.93

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$31.4M$37.0M
Gross Profit-$19.1M$22.7M
Operating Income--$19.7M-$24.2M
Net Income--$18.9M-$25.5M
Gross Margin-60.9%61.4%
Op. Margin--62.9%-65.4%
Net Margin--60.3%-69.1%
Balance Sheet
Total Assets$42.7M$39.2M$97.7M
Equity-$25.4M$28.0M
ROE--74.5%-91.1%
Per Share
EPS-$-0.70$-0.90
Cash Flow
Operating CF--$8.9M-$23.9M
CapEx$717K$275K$522K

Source: XBRL data in ClearPoint Neuro, Inc. (CLPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CLPT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CLPT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202619$73.6M
Q2 202621$108.9M
Q1 202620$53.5M
Q4 202522$88.0M
Q3 202519$119.5M
Q2 202521$63.2M
Q1 202514$36.9M
Q4 202411$37.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CLPT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
8-KOct 28, 2026Analysis-
10-QOct 28, 2026Analysis
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 3, 2026--
8-KAug 3, 2026Analysis-
10-QAug 3, 2026Analysis
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 1, 2026--
4Jun 22, 2026--
4Jun 8, 2026-
4Jun 2, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 21, 2026-
4May 21, 2026-

Related Health Care companies

All Health Care →

CLPT SEC filings: frequently asked questions

Which institutions hold CLPT stock?

As of September 30, 2026, the largest ClearPoint Neuro, Inc. (CLPT) holders among the 13F filers tracked by SignalX were BlackRock ($26.2 million), Vanguard Capital Management LLC ($15.0 million), State Street Corp ($10.7 million), Goldman Sachs Group ($4.3 million), Millennium Management ($3.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CLPT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90. The figures come from the XBRL data in the 10-K.

What did CLPT report in its latest 8-K?

ClearPoint Neuro, Inc. (CLPT) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). ATM equity capacity increased from $50 million to $150 million, expanding potential financing flexibility.

What are the latest CLPT SEC filings?

ClearPoint Neuro, Inc. (CLPT) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 2, 2026.

What is CLPT's SEC CIK number?

ClearPoint Neuro, Inc. (CLPT)'s SEC Central Index Key (CIK) is 1285550. EDGAR lists every CLPT filing under that number.

Ask anything about CLPT

The research agent reads CLPT's filings, financials, insider trades and 13F holders, then answers with sources.